Evidence map›Paper›PMID 25243787›Full record

ArticleThe Journal of investigative dermatology2015

Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival.

Jieyun Yin, Hongliang Liu, Zhensheng Liu, Li-E Wang, Wei V Chen, Dakai Zhu, Christopher I Amos, Shenying Fang, Jeffrey E Lee, Qingyi Wei

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Gene-Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jieyun Yin *Duke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Hongliang Liu *Duke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Zhensheng LiuDuke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Li-E WangDepartment of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA.
Wei V ChenDepartment of Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, USA.
Dakai ZhuCommunity and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, 03755, USA.
Christopher I AmosCommunity and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, 03755, USA.
Shenying FangDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA.
Jeffrey E LeeDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030, USA.
Qingyi WeiDuke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
Duke University · USThe University of Texas MD Anderson Cancer Center · USDartmouth College · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
Genetic Predictors for DNA Repair Phenotype in CMMR01CA100264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, QINGYI · 2004 to 2008
$1.5M
NCI NIH HHS P30 CA023108NCI NIH HHS P50 CA093459NCI NIH HHS R01 CA100264
6 · The paper itself

Abstract

Cutaneous melanoma (CM) is the most lethal skin cancer. The Fanconi anemia (FA) pathway involved in DNA crosslink repair may affect CM susceptibility and prognosis. Using data derived from published genome-wide association study, we comprehensively analyzed the associations of 2,339 common single-nucleotide polymorphisms (SNPs) in 14 autosomal FA genes with overall survival (OS) in 858 CM patients. By performing false-positive report probability corrections and stepwise Cox proportional hazards regression analyses, we identified significant associations between CM OS and four putatively functional SNPs: BRCA2 rs10492396 (AG vs. GG: adjusted hazard ratio (adjHR)=1.85, 95% confidence interval (CI)=1.16-2.95, P=0.010), rs206118 (CC vs. TT+TC: adjHR=2.44, 95% CI=1.27-4.67, P=0.007), rs3752447 (CC vs. TT+TC: adjHR=2.10, 95% CI=1.38-3.18, P=0.0005), and FANCA rs62068372 (TT vs. CC+CT: adjHR=1.85, 95% CI=1.27-2.69, P=0.001). Moreover, patients with an increasing number of unfavorable genotypes (NUG) of these loci had markedly reduced OS and melanoma-specific survival (MSS). The final model incorporating with NUG, tumor stage, and Breslow thickness showed an improved discriminatory ability to classify both 5-year OS and 5-year MSS. Additional investigations, preferably prospective studies, are needed to validate our findings.

Indexed as

Genes, BRCA2Genetic VariationAdolescentAdultAgedAged, 80 and overComputational BiologyFanconi AnemiaFanconi Anemia Complementation Group A ProteinFemaleHumansMaleMelanomaMiddle AgedPolymorphism, Single NucleotideProportional Hazards ModelsFANCA protein, humanFanconi Anemia Complementation Group A Protein

Identifiers

PMID25243787
PMCPMC4289462
OpenAlexW2079632548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.